DOCSLIB.ORG

Kinase-Independent Function of E-Type Cyclins in Liver Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kinase-Independent Function of E-Type Cyclins in Liver Cancer Kinase-independent function of E-type cyclins in liver cancer Yan Genga,b, Wojciech Michowskia,b, Joel M. Chickc, Yaoyu E. Wangd, M. Emmanuelle Jecroisa,b, Katharine E. Sweeneya,b, Lijun Liua,b, Richard C. Hana,b, Nan Kea,b, Agnieszka Zagozdzona,b, Ewa Sicinskae, Roderick T. Bronsonf, Steven P. Gygic, and Piotr Sicinskia,b,1 aDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; bDepartment of Genetics, Harvard Medical School, Boston, MA 02115; cDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115; dCenter for Cancer Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215; eDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215; and fDepartment of Biomedical Sciences, Tufts University Veterinary School, North Grafton, MA 01536 Edited by Mariano Barbacid, Spanish National Cancer Research Centre, Madrid, Spain, and approved December 20, 2017 (received for review June 26, 2017) E-type cyclins (cyclins E1 and E2) are components of the core cell for 745,000 deaths annually (10). The 5-y survival rate for patients cycle machinery and are overexpressed in many human tumor with HCC is only ∼7%. E cyclins are overexpressed in the majority of types. E cyclins are thought to drive tumor cell proliferation by HCC cases, while nearly 20% of tumors display amplification of the activating the cyclin-dependent kinase 2 (CDK2). The cyclin E1 gene CCNE1 and CCNE2 genes (11–14).ThemajorriskfactorsforHCC represents the site of recurrent integration of the hepatitis B virus are chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) in- in the pathogenesis of hepatocellular carcinoma, and this event fections (15). The CCNE1 gene represents one of the most frequent is associated with strong up-regulation of cyclin E1 expression. sites of HBV integration in HCC, and this event is associated with Regardless of the underlying mechanism of tumorigenesis, the strong up-regulation of cyclin E1 expression (16). Moreover, the majority of liver cancers overexpress E-type cyclins. Here we used hepatitis C virus core protein was shown to promote cell proliferation conditional cyclin E knockout mice and a liver cancer model to by up-regulating cyclin E levels (17). Regardless of the pathogenesis, test the requirement for the function of E cyclins in liver HCC occurs more than five times more frequently in males than in tumorigenesis. We show that a ubiquitous, global shutdown of females, and this was attributed in part to up-regulation of cyclin E GENETICS E cyclins did not visibly affect postnatal development or physi- expression by testosterone (18). Collectively, these findings suggest an ology of adult mice. However, an acute ablation of E cyclins halted important role for cyclin E in pathogenesis of HCC. liver cancer progression. We demonstrated that also human liver In this study, we tested the requirement for E cyclins in pro- cancer cells critically depend on E cyclins for proliferation. In contrast, gression of HCC using mouse cancer models. We report that E we found that the function of the cyclin E catalytic partner, CDK2, is cyclins play an essential, rate-limiting role in liver cancer progres- dispensable in liver cancer cells. We observed that E cyclins drive sion, while being dispensable for proliferation of normal tissues. proliferation of tumor cells in a CDK2- and kinase-independent Unexpectedly, we found that the function of E cyclins in liver mechanism. Our study suggests that compounds which degrade or cancer cell proliferation is independent of the canonical role of E inhibit cyclin E might represent a highly selective therapeutic strategy cyclins as activators of CDK2. for patients with liver cancer, as these compounds would selectively cripple proliferation of tumor cells, while sparing normal tissues. Results Cyclin E Function Is Dispensable in Postnatal Animals. We and others cell cycle | E-type cyclins | cyclin-dependent kinase CDK2 | liver cancer previously reported that constitutive, germline ablation of cyclin − − − − E1 and E2 resulted in an embryonic lethality of cyclin E1 / E2 / -type cyclins (cyclins E1 and E2, collectively called “cyclin EE”) are components of the core cell cycle machinery. These Significance two cyclins are encoded by separate genes and are usually coexpressed in proliferating cells (1). E-type cyclins bind and Amplification of the cyclin E genes and overexpression of cyclin E activate their kinase partner, the cyclin-dependent kinase 2 proteins is very frequent in several human tumor types. In partic- (CDK2). Cyclin E–CDK2 complexes phosphorylate proteins ular, overexpression of E cyclins was implicated in the pathogen- governing cell cycle progression, including the retinoblastoma pro- esis of liver cancers. According to the current cell division models, E tein and retinoblastoma-related p107 and p130 proteins, as well as cyclins drive tumor cell proliferation by activating its kinase part- proteins involved in histone biosynthesis, centrosome duplication, ner, the cyclin-dependent kinase 2 (CDK2). In this study, we dem- and firing of DNA replication origins (2). These functions of cyclin onstrate that E cyclins are dispensable for adult mouse physiology, E–CDK2 kinase promote progression of cells through the G1 phase but essential for liver cancer progression. Surprisingly, we found of the cell cycle and entry into DNA synthesis (S phase) (2). that the function of E cyclins in liver tumorigenesis is kinase in- Consistent with their growth-promoting roles, amplification of dependent. Our study suggests that agents targeting E cyclins the cyclin E1 and E2 genes (CCNE1 and CCNE2, respectively) would be efficacious in liver cancer treatment, as they would halt and pathological overexpression of their proteins have been proliferation of tumor cells while sparing normal tissues. documented in many cancer types (3–7). Indeed, the CCNE1 gene located on chromosome 19q12 represents one of the most fre- Author contributions: Y.G. and P.S. designed research; Y.G., W.M., J.M.C., M.E.J., K.E.S., L.L., R.C.H., N.K., A.Z., and E.S. performed research; W.M., J.M.C., and S.P.G. contributed quently amplified loci across all human tumor types (8). Over- new reagents/analytic tools; Y.G., Y.E.W., R.T.B., and P.S. analyzed data; and Y.G. and P.S. expression of E cyclins was shown to generally correlate with poor wrote the paper. clinical outcome (3, 4). In the case of HER2-positive breast can- Conflict of interest statement: P.S. is a consultant and a recipient of a research grant cers, cyclin E amplification/overexpression represents a molecular from Novartis. mechanism of resistance to trastuzumab (Herceptin) treatment This article is a PNAS Direct Submission. (9). It is currently assumed that overexpressed E cyclins drive the Published under the PNAS license. tumorigenic process through hyperactivation of the CDK2 kinase. 1To whom correspondence should be addressed. Email: [email protected]. Hepatocellular carcinoma (HCC) represents the second most This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. common cause of death from cancer worldwide, and it is responsible 1073/pnas.1711477115/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1711477115 PNAS Early Edition | 1of6 Downloaded by guest on September 27, 2021 mice due to placental and heart abnormalities (19, 20). To circum- S1 D and E). Importantly, efficient deletion of cyclin E1 was vent this lethality, and to study the requirement of cyclin E function maintained after 1 y even in highly proliferative organs such as at later stages of development, we generated a conditional cyclin intestine or spleens (Fig. S1B, see 1 y). We concluded that E E1 knockout (E1F/F) mouse strain (21). We interbred cyclin E1F/F cyclins are largely dispensable for proliferation of cells in post- − − − − and cyclin E2 / mice giving rise to cyclin E1F/FE2 / animals, which natal animals. Despite the efficient deletion of cyclin E1 after will be further referred to as “conditional cyclin E knockout” mice. Cre activation, we detected low levels of nondeleted floxed cyclin In the first set of experiments, we crossed conditional cyclin E E alleles in many organs (Fig. S1B). Hence, we cannot conclude knockout mice with Esr1-Cre animals (22), which ubiquitously that all cells within a given compartment do not require cyclin E. express tamoxifen-inducible Cre recombinase. Administration of tamoxifen to Esr1-Cre mice activates Cre, leading to a global Requirement for Cyclin E Function in Liver Cancer Progression. We deletion of the “floxed” sequences (22). We administered ta- next asked what the impact would be of cyclin E shutdown on − − moxifen to pregnant females bearing cyclin E1F/FE2 / embryos liver tumorigenesis. To efficiently delete both E cyclins in livers, at day 17.5 of gestation, and continued treatment of postnatal we turned to Mx1-Cre mice, which express inducible Cre animals with tamoxifen to ensure ubiquitous deletion of E cyclins recombinase. Administration of a double-stranded RNA analog (Fig. S1A). We then verified an efficient deletion of cyclin E1 in polyI–polyC to Mx1-Cre animals activates Cre, leading to nearly most organs analyzed (Fig. S1B, see P36) and observed the an- 100% deletion of the floxed sequences in liver and in the bone imals for 1 y. We found that an acute and global shutdown of E marrow cells (Fig. S2 A and B) (23). First, we administered − − cyclins did not compromise the animals’ viability and had no polyI–polyC to cyclin E1F/FE2 / /Mx1-Cre animals and de- outward effect on their health, except for slightly reduced body termined that ablation of both E cyclins had no effect on he- weights of cyclin E-deleted animals (Fig. S1C). Cyclin E-deleted matological parameters (Fig. S2 C and D). These findings are animals displayed normal biochemical parameters in the pe- consistent with the observation that bone marrow cells express ripheral blood and normal parameters of liver function (Fig.
Load more

Recommended publications
  • Original Article Expression of Cell-Cycle Regulators Is Associated with Invasive Behavior and Poor Prognosis in Prolactinomas
    Int J Clin Exp Pathol 2016;9(3):3245-3255 www.ijcep.com /ISSN:1936-2625/IJCEP0021009 Original Article Expression of cell-cycle regulators is associated with invasive behavior and poor prognosis in prolactinomas Chunhui Liu1,2*, Weiyan Xie1,2*, Dan Wu3, Zhenye Li2, Chuzhong Li1,2, Yazhuo Zhang1,2 1Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; 2Beijing Tiantan Hospital, Capital Medical University, Beijing, China; 3Department of Neurology, Beijing Renhe Hospital, Beijing, China. *Equal con- tributors. Received December 2, 2015; Accepted February 13, 2016; Epub March 1, 2016; Published March 15, 2016 Abstract: Prolactinomas are the most common pituitary tumors. The mechanisms of cell-cycle regulators underlying their invasive biological behavior and poor prognosis have not yet been fully clarified. We classified 48 human pro- lactinomas as invasive or non-invasive and determined cyclin D1, cyclin E1, p16, p27, Cdk2 and Cdk4 expression by immunohistochemistry analysis of tissue microarray constructs. Then we determined the diagnostic and prognostic value of the cell-cycle regulators expression in human prolactinomas. In this proof of principle study we found that nuclear p16 and p27 expression levels were much lower in invasive prolactinomas compared with non-invasive prolactinomas. Meanwhile, significantly higher cyclin D1 and cyclin E1 expression in invasive prolactinomas com- pared with normal pituitary or non-invasive prolactinomas. No difference was found in Cdk2 or Cdk4 protein levels in invasive or non-invasive prolactinomas. Regarding clinical outcome, the expression ratios of cyclin D1/p16 and cyclin E1/p27 were significantly positively correlated with clinically inferior outcome (P<0.001), while Cdk2 or Cdk4 expression showed no relationship with clinical outcome.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/26/2021 02:04:00PM Via Free Access
    26 1 Endocrine-Related N Portman et al. CDK4/6 inhibitor resistance in 26:1 R15–R30 Cancer breast cancer REVIEW Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer Neil Portman1,2, Sarah Alexandrou1,2, Emma Carson1,2, Shudong Wang3, Elgene Lim1,2 and C Elizabeth Caldon1,2 1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia 2St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia 3Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, South Australia, Australia Correspondence should be addressed to C E Caldon: [email protected] Abstract Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination Key Words with endocrine therapy, and they significantly increase the progression-free survival of f CDK4/6 inhibitors patients with advanced estrogen receptor-positive (ER+) breast cancer in the first-line f estrogen receptor treatment setting. As the new standard of care in some countries, there is the clinical f breast cancer emergence of patients with breast cancer that is both CDK4/6 inhibitor and endocrine f endocrine therapy therapy resistant. The strategies to combat these cancers with resistance to multiple treatments are not yet defined and represent the next major clinical challenge in ER+ breast cancer. In this review, we discuss how the molecular landscape of endocrine therapy resistance may affect the response to CDK4/6 inhibitors, and how this intersects with biomarkers of intrinsic insensitivity. We identify the handful of pre-clinical models of acquired resistance to CDK4/6 inhibitors and discuss whether the molecular changes in these models are likely to be relevant or modified in the context of endocrine therapy resistance.
    [Show full text]
  • The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression
    International Journal of Molecular Sciences Review The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression Tingting Zou and Zhenghong Lin * School of Life Sciences, Chongqing University, Chongqing 401331, China; [email protected] * Correspondence: [email protected] Abstract: The cell cycle is a collection of events by which cellular components such as genetic materials and cytoplasmic components are accurately divided into two daughter cells. The cell cycle transition is primarily driven by the activation of cyclin-dependent kinases (CDKs), which activities are regulated by the ubiquitin-mediated proteolysis of key regulators such as cyclins, CDK inhibitors (CKIs), other kinases and phosphatases. Thus, the ubiquitin-proteasome system (UPS) plays a pivotal role in the regulation of the cell cycle progression via recognition, interaction, and ubiquitination or deubiquitination of key proteins. The illegitimate degradation of tumor suppressor or abnormally high accumulation of oncoproteins often results in deregulation of cell proliferation, genomic instability, and cancer occurrence. In this review, we demonstrate the diversity and complexity of the regulation of UPS machinery of the cell cycle. A profound understanding of the ubiquitination machinery will provide new insights into the regulation of the cell cycle transition, cancer treatment, and the development of anti-cancer drugs. Keywords: cell cycle regulation; CDKs; cyclins; CKIs; UPS; E3 ubiquitin ligases; Deubiquitinases (DUBs) Citation: Zou, T.; Lin, Z. The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression. 1. Introduction Int. J. Mol. Sci. 2021, 22, 5754. https://doi.org/10.3390/ijms22115754 The cell cycle is a ubiquitous, complex, and highly regulated process that is involved in the sequential events during which a cell duplicates its genetic materials, grows, and di- Academic Editors: Kwang-Hyun Bae vides into two daughter cells.
    [Show full text]
  • TEAD4 Ensures Postimplantation Development by Promoting Trophoblast Self-Renewal: an Implication in Early Human Pregnancy Loss
    TEAD4 ensures postimplantation development by promoting trophoblast self-renewal: An implication in early human pregnancy loss Biswarup Sahaa,1,2, Avishek Gangulya,1, Pratik Homea,b, Bhaswati Bhattacharyaa, Soma Raya, Ananya Ghosha, M. A. Karim Rumia,b, Courtney Marshb,c, Valerie A. Frenchc, Sumedha Gunewardenad, and Soumen Paula,b,c,3 aDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160; bInstitute for Reproduction and Perinatal Research, University of Kansas Medical Center, Kansas City, KS 66160; cDepartment of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS 66160; and dDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160 Edited by R. Michael Roberts, University of Missouri, Columbia, MO, and approved June 22, 2020 (received for review February 12, 2020) Early pregnancy loss affects ∼15% of all implantation-confirmed Studies in mutant mouse models showed that failure in pla- human conceptions. However, evolutionarily conserved molecular centation often leads to in utero embryonic death (6, 7). Therefore, mechanisms that regulate self-renewal of trophoblast progenitors impaired placentation due to defective development or function of and their association with early pregnancy loss are poorly under- trophoblast cell lineages is considered one of the major underlying stood. Here, we provide evidence that transcription factor TEAD4 causes of early pregnancy loss. Disruptions of trophoblast pro- ensures survival of postimplantation mouse and human embryos genitor differentiation and defective placentation have also been by controlling self-renewal and stemness of trophoblast progeni- implicated as probable causes of pregnancy-associated compli- tors within the placenta primordium.
    [Show full text]
  • Mir-15 and Mir-16 Are Direct Transcriptional Targets of E2F1 That Limit E2F-Induced Proliferation by Targeting Cyclin E
    Molecular Cancer Cell Cycle, Cell Death, and Senescence Research miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E Matan Ofir, Dalia Hacohen, and Doron Ginsberg Abstract microRNAs (miR) are small noncoding RNA molecules that have recently emerged as critical regulators of gene expression and are often deregulated in cancer. In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death. E2F1 is a critical downstream target of the tumor suppressor retinoblastoma (RB). The RB pathway is often inactivated in human tumors resulting in deregulated E2F activity. We show that expression levels of the 4 mature miRs, miR-15a, miR-16-1 and miR-15b, miR-16-2, as well as their precursor pri- miRNAs, are elevated upon activation of ectopic E2F1. Moreover, activation of endogenous E2Fs upregulates expression of these miRs and endogenous E2F1 binds their respective promoters. Importantly, we corroborate that miR-15a/b inhibits expression of cyclin E, the latter a key direct transcriptional target of E2F pivotal for the G1/S transition, raising the possibility that E2F1, miR-15, and cyclin E constitute a feed-forward loop that modulates E2F activity and cell-cycle progression. In support of this, ectopic expression of miR-15 inhibits the G1/S transition, and, conversely, inhibition of miR-15 expression enhances E2F1-induced upregulation of cyclin E1 levels.
    [Show full text]
  • Cyclin E2, a Novel Human G1 Cyclin and Activating Partner of CDK2 and CDK3, Is Induced by Viral Oncoproteins
    Oncogene (1998) 17, 2787 ± 2798 ã 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins Maimoona Zariwala1, Jidong Liu2 and Yue Xiong*,1,2,3 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3280; 2Department of Biochemistry and Biophysics; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599- 3280; 3Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3280, USA G1 cyclin E controls the initiation of DNA synthesis by complexes with CDK4 or CDK6 to prevent the CDKs activating CDK2, and abnormally high levels of cyclin E from binding with and becoming activated by D-type expression have frequently been observed in human cyclins. The main function of CDK inhibitors is cancers. We have isolated a novel human cyclin, cyclin believed to couple diversi®ed growth inhibitory signals E2, that contains signi®cant homology to cyclin E. to the cell cycle clock. Cyclin E2 speci®cally interacts with CDK inhibitors of The decision to enter the replicative DNA synthesis the CIP/KIP family and activates both CDK2 and (S) phase or arrest in G1 is linked to diverse cellular CDK3. The expression of cyclin E2 mRNA oscillates processes such as signal transduction, cell differentia- periodically throughout the cell cycle, peaking at the tion, senescence, and oncogenic transformation G1/S transition, and exhibits a pattern of tissue (Hunter and Pines, 1994).
    [Show full text]
  • Tumour Kinome Re-Wiring Governs Resistance to Palbociclib in Oestrogen Receptor Positive Breast Cancers, Highlighting New Therapeutic Modalities
    Oncogene (2020) 39:4781–4797 https://doi.org/10.1038/s41388-020-1284-6 ARTICLE Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities 1 1 1 1 1 Sunil Pancholi ● Ricardo Ribas ● Nikiana Simigdala ● Eugene Schuster ● Joanna Nikitorowicz-Buniak ● 2 3 1 4 5 6 Anna Ressa ● Qiong Gao ● Mariana Ferreira Leal ● Amandeep Bhamra ● Allan Thornhill ● Ludivine Morisset ● 6 6 2 2 7 Elodie Montaudon ● Laura Sourd ● Martin Fitzpatrick ● Maarten Altelaar ● Stephen R. Johnston ● 6 1,8 1 Elisabetta Marangoni ● Mitch Dowsett ● Lesley-Ann Martin Received: 24 May 2019 / Revised: 18 March 2020 / Accepted: 24 March 2020 / Published online: 19 April 2020 © The Author(s) 2020. This article is published with open access Abstract Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)- positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than loss of RB1 few gene- copy number (CN) alterations are associated with irreversible-resistance to endocrine therapy and subsequent secondary 1234567890();,: 1234567890();,: resistance to palbociclib. Resistance to palbociclib occurred as a result of tumour cell re-wiring leading to increased expression of EGFR, MAPK, CDK4, CDK2, CDK7, CCNE1 and CCNE2. Resistance altered the ER genome wide-binding pattern, leading to decreased expression of ‘classical’ oestrogen-regulated genes and was accompanied by reduced sensitivity to fulvestrant and tamoxifen. Persistent CDK4 blockade decreased phosphorylation of tuberous sclerosis complex 2 (TSC2) enhancing EGFR signalling, leading to the re-wiring of ER. Kinome-knockdown confirmed dependency on ERBB- signalling and G2/M–checkpoint proteins such as WEE1, together with the cell cycle master regulator, CDK7.
    [Show full text]
  • Cyclin-Dependent Kinases and CDK Inhibitors in Virus-Associated Cancers Shaian Tavakolian, Hossein Goudarzi and Ebrahim Faghihloo*
    Tavakolian et al. Infectious Agents and Cancer (2020) 15:27 https://doi.org/10.1186/s13027-020-00295-7 REVIEW Open Access Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers Shaian Tavakolian, Hossein Goudarzi and Ebrahim Faghihloo* Abstract The role of several risk factors, such as pollution, consumption of alcohol, age, sex and obesity in cancer progression is undeniable. Human malignancies are mainly characterized by deregulation of cyclin-dependent kinases (CDK) and cyclin inhibitor kinases (CIK) activities. Viruses express some onco-proteins which could interfere with CDK and CIKs function, and induce some signals to replicate their genome into host’scells.By reviewing some studies about the function of CDK and CIKs in cells infected with oncoviruses, such as HPV, HTLV, HERV, EBV, KSHV, HBV and HCV, we reviewed the mechanisms of different onco-proteins which could deregulate the cell cycle proteins. Keywords: CDK, CIKs, Cancer, Virus Introduction the key role of the phosphorylation in the entrance of Cell division is controlled by various elements [1–10], the cells to the S phase of the cell cycle [19]. especially serine/ threonine protein kinase complexes, CDK genes are classified in mammalian cells into differ- called cyclin-dependent kinases (CDKs), and cyclins, ent classes of CDKs, especially some important regulatory whose expression is prominently regulated by the bind- ones (The regulatory CDKs play important roles in medi- ing to CDK inhibitors [11, 12]. In all eukaryotic species, ating cell cycle). Each of these CDKs could interact with a these genes are classified into different families. It is specific cyclin and thereby regulating the expression of well-established that the complexes of cyclin and CDK different genes [20, 21].
    [Show full text]
  • Reduction of Cdc25a Contributes to Cyclin E1-Cdk2 Inhibition at Senescence in Human Mammary Epithelial Cells
    Oncogene (2000) 19, 5314 ± 5323 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells Charanjit Sandhu1, Jerey Donovan1, Nandita Bhattacharya1, Martha Stampfer2, Peter Worland3 and Joyce Slingerland*,1 1Cancer Research, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; 2Life Sciences Division, Lawrence Berkeley Laboratory, University of California Berkeley, Berkeley, California, CA 94720, USA; 3Mitotix Incorporated, Cambridge, Massachusetts, MA 02139, USA Replicative senescence may be an important tumor a phenomenon known as cellular senescence (Hay¯ick, suppressive mechanism for human cells. We investigated 1965). Senescence may function as a tumor suppression the mechanism of cell cycle arrest at senescence in mechanism since the proliferative constraint imposed human mammary epithelial cells (HMECs) that have by senescence limits the accumulation of genetic errors undergone a period of `self-selection', and as a in the progeny of a single cell (Vojta and Barrett, consequence exhibit diminished p16INK4A levels. As 1995). The progressive reduction in telomere length HMECs approached senescence, the proportion of cells that occurs with successive cell divisions may govern with a 2N DNA content increased and that in S phase the point at which cells enter replicative senescence decreased progressively. Cyclin D1-cdk4, cyclin E-cdk2 (Bodnar et al., 1998; de Lange, 1998). Cultured human and cyclin A-cdk2 activities were not abruptly inhibited, ®broblasts show a predominantly 2N DNA content at but rather diminished steadily with increasing population senescence, re¯ecting cell cycle arrest in G1 phase age.
    [Show full text]
  • Cyclin E Provides a Link Between Cell Cycle, Dna
    CYCLIN E PROVIDES A LINK BETWEEN CELL CYCLE, DNA REPAIR AND APOPTOSIS A dissertation submitted to Kent State University in collaboration with the Lerner Research Institute, Cleveland Clinic in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Dragos Costin Plesca May, 2008 Dissertation written by Dragos Costin Plesca Pharm.D., University of Medicine and Pharmacy “Carol Davila”, Romania, 2002 Ph.D., Kent State University, 2008 Approved by ____________________, Chair, Doctoral Dissertation Committee Alexandru Almasan, Ph.D ____________________, Member, Doctoral Dissertation Committee James Blank, Ph.D ____________________, Member, Doctoral Dissertation Committee Gail Fraizer, Ph.D ____________________, Member, Doctoral Dissertation Committee Olena Piontkivska, Ph.D ____________________, Graduate Faculty Representative Jennifer Marcinkiewicz, Ph.D Accepted by ____________________, Director, School of Biomedical Sciences Robert V. Dorman, Ph.D ____________________, Dean, College of Arts and Sciences John R. D. Stalvey, Ph.D ii TABLE OF CONTENTS List of Figures.................................................................................................................vi List of Tables ..................................................................................................................ix Acknowledgments ............................................................................................................x Chapter I. Introduction ................................................................................................1
    [Show full text]
  • Cyclin E1 and Rb Modulation As Common Events at Time of Resistance to Palbociclib in Hormone Receptor-Positive Breast Cancer
    www.nature.com/npjbcancer ARTICLE OPEN Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer Cristina Guarducci1, Martina Bonechi1, Matteo Benelli2, Chiara Biagioni2,3, Giulia Boccalini1, Dario Romagnoli2, Roberto Verardo4, Rachel Schiff5,6,7,8, C. Kent Osborne5,6,7,8, Carmine De Angelis5,6,8, Angelo Di Leo3, Luca Malorni1,3 and Ilenia Migliaccio1 CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6 inhibitor palbociclib, and analyzed cell cycle-related markers by gene expression profiles (GEP) and western blot (WB). GEP showed high molecular heterogeneity among the models, with E2F targets being significantly enriched both during treatment and at the time of resistance. By both WB and GEP, a common molecular feature at the time of palbociclib resistance was the concomitant overexpression of cyclin E1 and down-regulation of Rb. CCNE1 was the only significantly up-regulated gene among E2F targets at resistance with CCNE1 genomic amplification being observed in two resistant models. Rb was downregulated in all resistant models; a reduction of RB1 copy number was observed in three resistant cell lines. In silico analyses showed that CCNE1/RB1 ratio correlated with palbociclib IC50 in different datasets of both breast and non-breast cancer cell lines, performing better than CCNE1 or RB1 taken separately. Finally, the CCNE1/RB1 ratio was shown to be an adverse prognostic factor in patients with ER+ BC and to be able to discriminate palbociclib-sensitive versus resistant among patients enrolled in the NeoPalAna trial, a neoadjuvant trial testing palbociclib, performing better than CCNE1 or RB1 alone.
    [Show full text]
  • Upregulation of CDKN2A and Suppression of Cyclin D1 Gene
    European Journal of Endocrinology (2010) 163 523–529 ISSN 0804-4643 CLINICAL STUDY Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas Yuji Tani, Naoko Inoshita1, Toru Sugiyama, Masako Kato, Shozo Yamada2, Masayoshi Shichiri3 and Yukio Hirata Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan, Departments of 1Pathology and 2Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo 105-8470, Japan and 3Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Kitasato University, Kanagawa 252-0375, Japan (Correspondence should be addressed to Y Hirata; Email: [email protected]) Abstract Objective: Cushing’s disease (CD) is usually caused by ACTH-secreting pituitary microadenomas, while silent corticotroph adenomas (SCA) are macroadenomas without Cushingoid features. However, the molecular mechanism(s) underlying their different tumor growth remains unknown. The aim of the current study was to evaluate and compare the gene expression profile of cell cycle regulators and cell growth-related transcription factors in CD, SCA, and non-functioning adenomas (NFA). Design and methods: Tumor tissue specimens resected from 43 pituitary tumors were studied: CD (nZ10), SCA (nZ11), and NFA (nZ22). The absolute transcript numbers of the following genes were quantified with real-time quantitative PCR assays: CDKN2A (or p16INK4a), cyclin family (A1, B1, D1, and E1), E2F1, RB1, BUB1, BUBR1, ETS1, and ETS2. Protein expressions of p16 and cyclin D1 were semi-quantitatively evaluated by immunohistochemical study. Results and conclusion: CDKN2A gene expression was about fourfold greater in CD than in SCA and NFA.
    [Show full text]